Abivax SA American Depositary Shares

The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant mark...

Abivax SA resumed trading of its ordinary shares on Euronext Paris on July 1, 2026, following a temporary halt. The company announced the pricing of an oversubscribed and upsized public offering of American Depositary Shares, increased from the previously announced $600M to $800M at $125.00 per share.

Abivax SA announced a temporary suspension of its ordinary shares trading on Euronext Paris starting July 1, 2026 at market opening. The suspension is related to the company's public offering of American Depositary Shares (ADS) in the United States to confirm investor allocations and announce final offering terms. Trading is expected to resume ar...

Abivax SA announced a temporary trading halt of its ordinary shares on Euronext Paris effective July 1, 2026, from market opening at 9:00 a.m. CEST. The halt is in connection with the company's public offering of American Depositary Shares in the United States to allow for allocation confirmation and pricing announcement. Trading is expected to r...

Abivax stock rose 3.46% on Thursday despite concerns following the release of Phase 3 trial data for obefazimod in ulcerative colitis. While the drug met primary endpoints with remission rates exceeding 50%, reported cancer cases during the trial have raised safety concerns among investors. The stock trades below its moving averages, with momentu...